+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

2019 Chemotherapy Induced Peripheral Neuropathy Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767605
  • Report
  • 79 pages
  • VPA Research
UP TO OFF
until Sep 30th 2019
1 of 3

FEATURED COMPANIES

  • Ajanta Pharma Ltd
  • AlfaSigma SpA
  • Johnson & Johnson
  • Pfizer Inc
  • PledPharma AB
  • Sanofi
  • MORE
The global clinical trial report- “2019 Chemotherapy Induced Peripheral Neuropathy Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Chemotherapy Induced Peripheral Neuropathy. It presents in-depth analysis of Chemotherapy Induced Peripheral Neuropathy clinical trials across markets and companies. The research work is for providing complete understanding into trends in Chemotherapy Induced Peripheral Neuropathy.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Chemotherapy Induced Peripheral Neuropathy clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Chemotherapy Induced Peripheral Neuropathy

The research work is prepared through extensive and continuous research on Chemotherapy Induced Peripheral Neuropathy trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Chemotherapy Induced Peripheral Neuropathy patients are identified
  • The report includes panorama of Chemotherapy Induced Peripheral Neuropathy clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Chemotherapy Induced Peripheral Neuropathy clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Ajanta Pharma Ltd
  • AlfaSigma SpA
  • Johnson & Johnson
  • Pfizer Inc
  • PledPharma AB
  • Sanofi
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Chemotherapy Induced Peripheral Neuropathy Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Chemotherapy Induced Peripheral Neuropathy Clinical Trials by Region
2.2.2 Average Enrollment of Chemotherapy Induced Peripheral Neuropathy Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Chemotherapy Induced Peripheral Neuropathy Treatment, 2019

3. Region wise Chemotherapy Induced Peripheral Neuropathy Clinical Trials
3.1 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Clinical Trials by Country
3.2 Europe Chemotherapy Induced Peripheral Neuropathy Clinical Trials by Country
3.3 North America Chemotherapy Induced Peripheral Neuropathy Clinical Trials by Country
3.4 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Clinical Trials by Country
3.5 South and Central America Chemotherapy Induced Peripheral Neuropathy Clinical Trials by Country

4. Chemotherapy Induced Peripheral Neuropathy Clinical Trial Trends
4.1 Start Year wise Chemotherapy Induced Peripheral Neuropathy Clinical Trials
4.2 Phase wise Chemotherapy Induced Peripheral Neuropathy Clinical Trials
4.3 Trial Status wise Chemotherapy Induced Peripheral Neuropathy Clinical Trials
4.4 Trial Type wise Chemotherapy Induced Peripheral Neuropathy Clinical Trials

5. Chemotherapy Induced Peripheral Neuropathy Average Enrollment Trends
5.1 Average Enrollment in Chemotherapy Induced Peripheral Neuropathy Trials by Year
5.2 Average Enrollment in Chemotherapy Induced Peripheral Neuropathy Trials by Phase
5.3 Average Enrollment in Chemotherapy Induced Peripheral Neuropathy Trials by Status
5.4 Average Enrollment in Chemotherapy Induced Peripheral Neuropathy Trials by Type of Trial

6. Companies Participating in Chemotherapy Induced Peripheral Neuropathy Clinical Trials
6.1 Chemotherapy Induced Peripheral Neuropathy Trials by Sponsor Type
6.2 Chemotherapy Induced Peripheral Neuropathy Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Chemotherapy Induced Peripheral Neuropathy Trials- Phase 1
7.2 Chemotherapy Induced Peripheral Neuropathy Trials- Phase 2
7.3 Chemotherapy Induced Peripheral Neuropathy Trials- Phase 3
7.4 Chemotherapy Induced Peripheral Neuropathy Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Chemotherapy Induced Peripheral Neuropathy Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Chemotherapy Induced Peripheral Neuropathy Clinical Trials and Enrolment
Figure 5: Europe - Country wise Chemotherapy Induced Peripheral Neuropathy Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Chemotherapy Induced Peripheral Neuropathy Clinical Trials and Enrolment
Figure 7: North America - Country wise Chemotherapy Induced Peripheral Neuropathy Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Chemotherapy Induced Peripheral Neuropathy Clinical Trials and Enrolment
Figure 9: Chemotherapy Induced Peripheral Neuropathy Clinical Trials by Phase
Figure 10: Chemotherapy Induced Peripheral Neuropathy Clinical Trials by Trial Status
Figure 11: Chemotherapy Induced Peripheral Neuropathy Clinical Trials by Type
Figure 12: Chemotherapy Induced Peripheral Neuropathy Clinical Trials by Sponsor Type
Figure 13: Chemotherapy Induced Peripheral Neuropathy Clinical Trials by Leading Sponsors
Figure 14: Chemotherapy Induced Peripheral Neuropathy Average Enrollment by Phase
Figure 15: Chemotherapy Induced Peripheral Neuropathy Average Enrollment by Trial Status
Figure 16: Chemotherapy Induced Peripheral Neuropathy Average Enrollment by Type
Figure 17: Chemotherapy Induced Peripheral Neuropathy- Average Enrolment by Type of Sponsors
Figure 18: Chemotherapy Induced Peripheral Neuropathy- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Chemotherapy Induced Peripheral Neuropathy Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Chemotherapy Induced Peripheral Neuropathy Clinical Trials and Enrolment
Table 5: Europe - Country wise Chemotherapy Induced Peripheral Neuropathy Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Chemotherapy Induced Peripheral Neuropathy Clinical Trials and Enrolment
Table 7: North America - Country wise Chemotherapy Induced Peripheral Neuropathy Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Chemotherapy Induced Peripheral Neuropathy Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Chemotherapy Induced Peripheral Neuropathy Average Enrollment by Phase
Table 15: Chemotherapy Induced Peripheral Neuropathy Average Enrollment by Trial Status
Table 16: Chemotherapy Induced Peripheral Neuropathy Average Enrollment by Type
Table 17: Chemotherapy Induced Peripheral Neuropathy- Average Enrolment by Type of Sponsors
Table 18: Chemotherapy Induced Peripheral Neuropathy- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Ajanta Pharma Ltd
  • AlfaSigma SpA
  • Apexian Pharmaceuticals Inc
  • Immune Pharmaceuticals Inc
  • Johnson & Johnson
  • Pfizer Inc
  • PledPharma AB
  • Sanofi
  • Solasia Pharma KK
  • Winsantor Inc
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4767605
Adroll
adroll